Welcome to SageMedic
Supporting More Informed Treatment
Decisions
Within NCCN Guidelines
Provide laboratory insights to support treatment decision-making within NCCN guidelines.
The SAGE Oncotest™
Difference
The SAGE Oncotest™ is our validated ex-vivo drug response assay that provides clinically relevant laboratory insights from fresh tissue samples suitable for laboratory evaluation within 7- 10 days, regardless of whether targetable genomic alterations are identified.
Complementing Genomic Testing
With
Functional Profiling
The SAGE Oncotest™ is designed to complement genomic testing as part of a broader treatment evaluation approach. Published studies suggest that targetable genomic alterations may not be identified in all patients with solid tumors, and functional profiling may provide additional laboratory insights in these situations.¹
It is not a substitute for genomic testing but may help support individualized treatment planning as part of precision oncology care.
Preserving Important
Tumor Characteristics
A surgically collected fresh tissue biopsy is shipped to SAGE overnight. Upon arrival, tissue is processed into multiple testable tissue samples suitable for laboratory evaluation. These samples preserve important characteristics of the original biopsy and are evaluated against NCCN guideline recommended treatment options over several days. Laboratory results are then reported to the treating physician within 7-10 days.
We prepare testable tissue samples for laboratory evaluation within one day.
We preserve important biological characteristics of the original sample.
Evaluating multiple FDA-approved treatment options using our proprietary technologies.
To provide laboratory insights that support treatment decision-making within 7-10 days.
Laboratory Assessment of
Drug Resistance Patterns
Support treatment decision-making by evaluating potential drug resistance patterns.
Our predicate ex-vivo extreme drug resistance (EDR) assay (see figure): Limited response of ex-vivo cancer tissue to supraphysiological doses has been associated with resistance patterns observed in validation studies.
Evaluate potential multi-drug resistance patterns to support treatment planning.
Clinically Relevant
Laboratory Insights
Laboratory Assessment of Tumor Resistance Patterns
The SAGE Oncotest™ builds upon published validation studies involving ex-vivo extreme drug resistance (EDR) assays that evaluated laboratory resistance patterns in cancer tissue.
Laboratory evaluation of potential resistance patterns may help support individualized treatment planning discussions, particularly in complex treatment settings.
When Clinicians Use
The SAGE Oncotest
A common scenario clinicians face is a number of NCCN recommended regimens with the latitude to choose the most appropriate intervention for each patient.
-
-
Ovarian Cancer
-
Gastrointestinal Cancers
-
Clinicians can request evaluation of additional physician-selected treatment agents on a case-by-case basis.
The SAGE Oncotest™ results may help support treatment planning discussions in complex oncology settings, including evaluation of additional treatment considerations and potential resistance patterns.
-
-
Cancers of Unknown Origin
-
Ascites or pleural effusions specimens
-
Physician-requested evaluations
-
